类风湿关节炎与系统性红斑狼疮新使用羟氯喹者的心律失常风险:一项基于人群的研究
在加拿大不列颠哥伦比亚省1996年1月至2014年12月期间,从行政数据库中识别新发类风湿关节炎或系统性红斑狼疮且无心律失常事件、未用抗心律失常药及羟氯喹的患者,按倾向评分1:1匹配羟氯喹启用者与未启用者各11,518例,平均随访8年。羟氯喹启用组发生1,610例新发心律失常,未启用组1,646例,粗发生率分别为17.5/1000人年与18.1/1000人年,校正病因特异性风险比0.96(95%CI 0.89-1.03)。结论认为新使用羟氯喹者任何类型心律失常风险未增加。
要点
- 倾向评分匹配后羟氯喹启用者与未启用者各11,518例,平均随访8年。
- 任何心律失常校正病因特异性风险比0.96(95%CI 0.89-1.03),未达统计学显著。
- 房颤、心电图异常及其他未特指心律失常的校正风险比均未达统计学显著。
核心结论
- 新使用羟氯喹者任何类型心律失常风险未增加。
研究设计与样本
- 基于加拿大不列颠哥伦比亚省1996年1月至2014年12月行政数据库的基于人群研究,纳入新发类风湿关节炎或系统性红斑狼疮且无心律失常事件、未用抗心律失常药及羟氯喹的患者,按倾向评分1:1匹配羟氯喹启用者与未启用者各11,518例。
主要发现
- 平均随访8年,羟氯喹启用组发生1,610例新发心律失常,未启用组1,646例,粗发生率分别为17.5/1000人年与18.1/1000人年。
- 羟氯喹启用者 compared with 未启用者 any arrhythmia 的校正病因特异性风险比为0.96(95%CI 0.89-1.03)。
- 房颤的校正病因特异性风险比为0.93(95%CI 0.83-1.04),心电图异常的为0.98(95%CI 0.87-1.11),其他未特指心律失常的为0.95(95%CI 0.84-1.07)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We assessed the association between hydroxychloroquine (HCQ) initiation and risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident systemic lupus erythematosus (SLE). METHODS: All patients with incident RA or SLE and no arrhythmic events, not receiving antiarrhythmic medications, and not receiving HCQ prior to the index date of disease in British Columbia, Canada, between January 1996 and December 2014 were identified from administrative databases. We identified patients who were dispensed HCQ prescriptions (HCQ initiators) or were not dispensed HCQ prescriptions (HCQ noninitiators) during each study year; groups were matched 1:1 by propensity scores using baseline confounders on demographics, comorbidities, medications, and health care utilization. Outcomes were any new arrhythmias, atrial fibrillation, abnormal electrocardiograms, including long QT syndrome and conduction disorder, and other unspecified arrhythmias during follow-up. We used cause-specific Cox proportional hazards models with death as a competing event to assess the association between HCQ initiation and the outcomes. RESULTS: We identified 11,518 propensity score-matched patients with RA or SLE in each group. Over the mean follow-up of 8 years, there were 1,610 and 1,646 incident arrhythmias in the HCQ initiator group and the noninitiator group, respectively, with crude incidence rates of arrhythmia of 17.5 and 18.1 in 1,000 persons per year, respectively. The adjusted cause-specific hazard ratio (cHR) for patients who received HCQ was 0.96 (95% confidence interval [95% CI] 0.89-1.03) compared with HCQ noninitiators, and the cHRs for patients who took HCQ and had arrhythmia subtypes of atrial fibrillation, abnormal electrocardiograms, and other unspecified arrhythmias were 0.93 (95% CI 0.83-1.04), 0.98 (95% CI 0.87-1.11), and 0.95 (95% CI 0.84-1.07), respectively. CONCLUSION: Risk of any type of arrhythmia was not increased among new users of HCQ.
引用
- Hoque MR, Lu L, Daftarian N, et al. Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study. Arthritis Rheumatol. 2023. PMID: 36054570. doi:10.1002/art.42337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。